Literature DB >> 18697922

Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs.

Ryan L Boudreau1, Alex Mas Monteys, Beverly L Davidson.   

Abstract

RNA interference (RNAi) is a cellular process regulating gene expression and participating in innate defense in many organisms. RNAi has also been utilized as a tool to query gene function and is being developed as a therapeutic strategy for several diseases. Synthetic small interfering (siRNAs) or expressed stem-loop RNAs (short-hairpin RNAs [shRNAs] or artificial microRNAs [miRNAs]) have been delivered to cultured cells and organisms to inhibit expression of a variety of genes. A persistent question in the field, however, is which RNAi expression system is most suitable for distinct applications. To date, shRNA- and artificial miRNA-based strategies have been compared with conflicting results. In prior comparisons, sequences required for efficient RNAi processing and loading of the intended antisense strand into the RNAi-induced silencing complex (RISC) were not considered. We therefore revisited the shRNA-miRNA comparison question. Initially, we developed an improved artificial miRNA vector and confirmed the optimal shRNA configuration by altering structural features of these RNAi substrates. Subsequently, we engineered and compared shRNA- and miRNA-based RNAi expression vectors that would be processed to yield similar siRNAs that exhibit comparable strand biasing. Our results demonstrate that when comparison variables are minimized, the shRNAs tested were more potent than the artificial miRNAs in mediating gene silencing independent of target sequence and experimental setting (in vitro and in vivo). In addition, we show that shRNAs are expressed at considerably higher levels relative to artificial miRNAs, thus providing mechanistic insight to explain their increased potency.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18697922      PMCID: PMC2525944          DOI: 10.1261/rna.1062908

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  39 in total

1.  Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells.

Authors:  Yan Zeng; Eric J Wagner; Bryan R Cullen
Journal:  Mol Cell       Date:  2002-06       Impact factor: 17.970

2.  Sequence requirements for micro RNA processing and function in human cells.

Authors:  Yan Zeng; Bryan R Cullen
Journal:  RNA       Date:  2003-01       Impact factor: 4.942

3.  Mfold web server for nucleic acid folding and hybridization prediction.

Authors:  Michael Zuker
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

Review 4.  Gene silencing in mammals by small interfering RNAs.

Authors:  Michael T McManus; Phillip A Sharp
Journal:  Nat Rev Genet       Date:  2002-10       Impact factor: 53.242

5.  Induction of an interferon response by RNAi vectors in mammalian cells.

Authors:  Alan J Bridge; Stephanie Pebernard; Annick Ducraux; Anne-Laure Nicoulaz; Richard Iggo
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

6.  Ribonuclease activity and RNA binding of recombinant human Dicer.

Authors:  Patrick Provost; David Dishart; Johanne Doucet; David Frendewey; Bengt Samuelsson; Olof Rådmark
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

7.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

8.  siRNA-mediated gene silencing in vitro and in vivo.

Authors:  Haibin Xia; Qinwen Mao; Henry L Paulson; Beverly L Davidson
Journal:  Nat Biotechnol       Date:  2002-09-16       Impact factor: 54.908

9.  RNA interference targeting Fas protects mice from fulminant hepatitis.

Authors:  Erwei Song; Sang-Kyung Lee; Jie Wang; Nedim Ince; Nengtai Ouyang; Jun Min; Jisheng Chen; Premlata Shankar; Judy Lieberman
Journal:  Nat Med       Date:  2003-02-10       Impact factor: 53.440

10.  Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.

Authors:  Jodi L McBride; Ryan L Boudreau; Scott Q Harper; Patrick D Staber; Alex Mas Monteys; Inâs Martins; Brian L Gilmore; Haim Burstein; Richard W Peluso; Barry Polisky; Barrie J Carter; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-08       Impact factor: 11.205

View more
  68 in total

1.  Identifying functional microRNAs in macrophages with polarized phenotypes.

Authors:  Joel W Graff; Anne M Dickson; Gwendolyn Clay; Anton P McCaffrey; Mary E Wilson
Journal:  J Biol Chem       Date:  2012-05-01       Impact factor: 5.157

2.  RNAimmuno: a database of the nonspecific immunological effects of RNA interference and microRNA reagents.

Authors:  Marta Olejniczak; Paulina Galka-Marciniak; Katarzyna Polak; Andrzej Fligier; Wlodzimierz J Krzyzosiak
Journal:  RNA       Date:  2012-03-12       Impact factor: 4.942

3.  Optimization and apoptosis induction by RNAi with UTMD technology in vitro.

Authors:  Zhi-Yi Chen; Kun Liang; Xiu-Jie Sheng; Bing Si-Tu; Xiao-Fang Sun; Jian-Qiao Liu; Ri-Xiang Qiu; Hua Zhang; Yue-Wei Li; Xin-Xin Zhou; Jiang-Xiu Yu
Journal:  Oncol Lett       Date:  2012-02-15       Impact factor: 2.967

4.  Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease.

Authors:  Ryan L Boudreau; Ryan M Spengler; Beverly L Davidson
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

5.  Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform.

Authors:  Mario Amendola; Laura Passerini; Ferdinando Pucci; Bernhard Gentner; Rosa Bacchetta; Luigi Naldini
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

6.  Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo.

Authors:  Ryan L Boudreau; Inês Martins; Beverly L Davidson
Journal:  Mol Ther       Date:  2008-11-11       Impact factor: 11.454

Review 7.  Lentiviral vector-mediated RNA silencing in the central nervous system.

Authors:  Thomas H Hutson; Edmund Foster; Lawrence D F Moon; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther Methods       Date:  2013-11-01       Impact factor: 2.396

8.  Structure and activity of putative intronic miRNA promoters.

Authors:  Alex Mas Monteys; Ryan M Spengler; Ji Wan; Luis Tecedor; Kimberly A Lennox; Yi Xing; Beverly L Davidson
Journal:  RNA       Date:  2010-01-14       Impact factor: 4.942

9.  RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1.

Authors:  Megan S Keiser; James C Geoghegan; Ryan L Boudreau; Kim A Lennox; Beverly L Davidson
Journal:  Neurobiol Dis       Date:  2013-04-10       Impact factor: 5.996

10.  Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.

Authors:  Christina E Khodr; Amanda Becerra; Ye Han; Martha C Bohn
Journal:  Brain Res       Date:  2014-01-21       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.